Related Experiment Videos
Targeting the molecular basis for tumour hypoxia
Veronica A Carroll1, Margaret Ashcroft
1Cell Growth Regulation and Angiogenesis Laboratory, Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK. veronica.carroll@icr.ac.uk
Expert Reviews in Molecular Medicine
|April 16, 2005
Summary
Tumour hypoxia, a lack of oxygen in tumors, leads to treatment resistance and poor prognosis. Targeting hypoxia-inducible factor (HIF) offers a promising strategy for developing new cancer therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Tumour hypoxia arises from poor blood supply and disorganized vasculature.
- Hypoxic tumors exhibit resistance to chemotherapy and radiation, correlating with poor patient outcomes.
- Hypoxia drives gene expression for cell survival and angiogenesis.
Purpose of the Study:
- To investigate the role of hypoxia-inducible factor (HIF) in regulating hypoxia-activated genes.
- To explore the potential of targeting HIF for cancer therapy.
Main Methods:
- Analysis of gene expression patterns under hypoxic conditions.
- Investigating the regulatory function of HIF in cancer cells.
Main Results:
- Hypoxia-inducible factor (HIF) is a key regulator of hypoxia-induced gene expression.
- HIF influences pathways critical for tumor cell survival and angiogenesis.
Conclusions:
- Hypoxia-inducible factor (HIF) is a critical mediator of tumor response to hypoxia.
- Targeting HIF and hypoxia-activated pathways represents a promising therapeutic strategy for improving cancer treatment outcomes.